Plus   Neg

Bristol-Myers: FDA To Review BLA For Liso-cel - Quick Facts

Bristol-Myers Squibb Company (BMY) announced the U.S. FDA has accepted for Priority Review its Biologics License Application for lisocabtagene maraleucel, or liso-cel, for adult patients with Relapsed or Refractory Large B-Cell Lymphoma. Liso-cel is an investigational compound that is not approved for use in any country.

Liso-cel was previously granted Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations by the FDA for R/R aggressive large B-cell non-Hodgkin lymphoma and Priority Medicines (PRIME) scheme by the European Medicines Agency for R/R diffuse large B-cell lymphoma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apotex Corp. recalled all lots of type 2 diabetes medication Metformin hydrochloride in the form of oral film-coated tablets for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Groupe Renault plans to cut about 14,600 jobs across the world and lower its production capacity. The plan includes almost 4,600 jobs reduction in France, through voluntary retirement and retraining. Amazon said it will convert 125,000 of the 175,000 temporary workers it hired in March amid the coronavirus pandemic, to permanent full-time employees in June. The e-commerce giant had hired the temporary employees in March to meet strong consumer demand amid the lockdown. The job openings were in Amazon's fulfillment centers and its delivery network.
Follow RTT